Dupont Capital Management Corp Sells 3,423 Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Dupont Capital Management Corp reduced its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 19.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,422 shares of the company’s stock after selling 3,423 shares during the period. Dupont Capital Management Corp’s holdings in Aerie Pharmaceuticals were worth $277,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of AERI. BlackRock Inc. boosted its position in shares of Aerie Pharmaceuticals by 11.0% in the 2nd quarter. BlackRock Inc. now owns 3,358,901 shares of the company’s stock worth $99,255,000 after purchasing an additional 331,884 shares during the last quarter. C WorldWide Group Holding A S boosted its position in shares of Aerie Pharmaceuticals by 235.0% in the 2nd quarter. C WorldWide Group Holding A S now owns 456,142 shares of the company’s stock worth $13,479,000 after purchasing an additional 320,000 shares during the last quarter. Waddell & Reed Financial Inc. boosted its position in shares of Aerie Pharmaceuticals by 14.8% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 1,737,627 shares of the company’s stock worth $51,347,000 after purchasing an additional 224,655 shares during the last quarter. Bamco Inc. NY boosted its position in shares of Aerie Pharmaceuticals by 400.7% in the 2nd quarter. Bamco Inc. NY now owns 275,226 shares of the company’s stock worth $8,133,000 after purchasing an additional 220,263 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB boosted its position in shares of Aerie Pharmaceuticals by 82.7% in the 3rd quarter. Rhenman & Partners Asset Management AB now owns 475,000 shares of the company’s stock worth $9,130,000 after purchasing an additional 215,000 shares during the last quarter.

In other news, CEO Vicente Anido, Jr. purchased 26,250 shares of the company’s stock in a transaction on Monday, September 9th. The shares were purchased at an average price of $19.01 per share, with a total value of $499,012.50. Following the purchase, the chief executive officer now directly owns 195,631 shares of the company’s stock, valued at approximately $3,718,945.31. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Foresite Capital Management Ii purchased 189,555 shares of the company’s stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $24.43 per share, for a total transaction of $4,630,828.65. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 562,698 shares of company stock worth $13,088,866. Corporate insiders own 8.71% of the company’s stock.

Several research analysts have recently issued reports on AERI shares. Stifel Nicolaus reduced their price target on Aerie Pharmaceuticals from $77.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday. JMP Securities reduced their price target on Aerie Pharmaceuticals to $41.00 and set an “outperform” rating on the stock in a research report on Thursday. Mizuho reiterated a “buy” rating and set a $54.00 target price (down from $63.00) on shares of Aerie Pharmaceuticals in a report on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $54.00 target price on shares of Aerie Pharmaceuticals in a report on Friday, October 25th. Finally, BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $44.92.

AERI stock opened at $19.23 on Friday. The business’s 50-day moving average price is $21.03 and its two-hundred day moving average price is $27.38. The company has a current ratio of 2.52, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.09 billion, a PE ratio of -4.14 and a beta of 0.51. Aerie Pharmaceuticals Inc has a 1-year low of $17.51 and a 1-year high of $50.10.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.02). The business had revenue of $18.54 million for the quarter, compared to the consensus estimate of $17.59 million. Aerie Pharmaceuticals had a negative return on equity of 89.52% and a negative net margin of 478.81%. On average, analysts forecast that Aerie Pharmaceuticals Inc will post -3.61 earnings per share for the current year.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Further Reading: What is Put Option Volume?

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.